StockData
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AgomAb Therapeutics NV

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026
$8.23−0.05 (-0.60%)

Close on Oct 19, 2026

SEC filings

12 of AgomAb Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report6-KOct 13, 2026Oct 13, 2026SEC EDGAR
Current report6-KOct 1, 2026Oct 1, 2026SEC EDGAR
Current report6-KSep 14, 2026Sep 14, 2026SEC EDGAR
Current report6-KSep 11, 2026Sep 11, 2026SEC EDGAR
Current report6-KAug 10, 2026Aug 10, 2026SEC EDGAR
Current report6-KAug 6, 2026Aug 6, 2026SEC EDGAR
Current report6-KJun 23, 2026Jun 23, 2026SEC EDGAR
Current report6-KMay 27, 2026May 27, 2026SEC EDGAR
Current report6-KApr 24, 2026Apr 24, 2026SEC EDGAR
Annual report20-FDec 31, 2025Apr 23, 2026SEC EDGAR
Current report6-KMar 5, 2026Mar 5, 2026SEC EDGAR
Current report6-KFeb 9, 2026Feb 9, 2026SEC EDGAR